Day One Biopharmaceuticals Inc. , which specializes in developing cancer treatments for children, upsized its initial public offering on Wednesday to 10 million shares from a previous plan to offer 8.4 million. The company is still proposing a price range of $14 to $16 a share. Day One said it expects proceeds of about $135.5 million at the midpoint of that range, or about $156.4 million if the underwriters exercise an option to buy up to an additional 1.5 million shares. The company has applied to list on Nasdaq, under the ticker “DAWN.” JPMorgan, Cowen, Piper Sandler and Wedbush PacGrow are underwriting the deal. Proceeds will be used to finance clinical trials and for working capital and general corporate purposes.” Day One was founded to address a critical unmet need: children with cancer are being left behind in a cancer drug development revolution,” the company says in its prospectus. “Our name was inspired by the “The Day One Talk” that physicians have with patients and their families about an initial cancer diagnosis and treatment plan. We aim to re-envision cancer drug development and redefine what’s possible for all people living with cancer-regardless of age-starting from Day One.”
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
